Search results
Showing 8671 to 8685 of 9045 results
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued Reference number: GID-TA11108
In development Reference number: GID-TA11449 Expected publication date: TBC
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Discontinued Reference number: GID-TA11357
In development Reference number: GID-TA11214 Expected publication date: TBC
Discontinued Reference number: GID-TA11204
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.
New life-extending treatment given the green light for people with rare form of bile duct cancer
A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.